RxDoctor Payments Data

Emil Kheterpal, MD

Urology · Raleigh, NCNPI 1437369691

Payments from drug & device makers

$9,820in general payments, 2019–2025

Across 313 payments — averaging $31.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Neotract Inc.$1K
  • Bayer$1K
  • Axonics, Inc.$1K
  • Astellas Pharma US Inc$562
  • Dendreon Pharmaceuticals LLC$519
  • plus $4K from 41 others

What the payments were for

  • Consulting fees$8729%
  • Travel & lodging$1,58416%
  • Food & beverage$6,76069%
  • Education$6046%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,820 in reported general payments places this provider in the 75th percentile of 434 urology providers in North Carolina.

See all urology providers in North Carolina

Medicare billing

Part B allowed, 2024
$329,255
Medicare patients
692
Services billed
6,362

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide109$1,239,950
XtandiEnzalutamide89$1,018,663
NubeqaDarolutamide48$529,841
OrgovyxRelugolix161$461,139
GemtesaVibegron116$127,956
MyrbetriqMirabegron52$47,801
Tamsulosin Hcl881$13,459
Testosterone40$10,369
Finasteride481$6,915
Trimethoprim49$2,834
Abiraterone Acetate12$2,655
Estradiol33$2,013
Alfuzosin Hcl ErAlfuzosin Hcl77$1,451
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst42$1,422
Testosterone Cypionate39$1,246

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$1,396$1,239,950109 claims
Astellas Pharma US IncXtandi, Myrbetriq$562$1,066,464141 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$465$589,095277 claims
BayerNubeqa$1,271$529,84148 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 434 urology providers in North Carolina.

Other urology in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →